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PTX3 is a prototypic soluble pattern recognition receptor, expressed at sites of
inflammation and involved in regulation of the tissue homeostasis. PTX3 systemic levels
increase in many (but not all) immune-mediated inflammatory conditions. Research on
PTX3 as a biomarker has so far focused on single diseases. Here, we performed a
multi-group comparative study with the aim of identifying clinical and pathophysiological
phenotypes associated with PTX3 release. PTX3 concentration was measured by
ELISA in the plasma of 366 subjects, including 96 patients with giant cell arteritis
(GCA), 42 with Takayasu’s arteritis (TA), 10 with polymyalgia rheumatica (PMR), 63
with ANCA-associated systemic small vessel vasculitides (AAV), 55 with systemic
lupus erythematosus (SLE), 21 with rheumatoid arthritis (RA) and 79 healthy controls
(HC). Patients with SLE, AAV, TA and GCA, but not patients with RA and PMR,
had higher PTX3 levels than HC. PTX3 concentration correlated with disease activity,
acute phase reactants and prednisone dose. It was higher in females, in patients with
recent-onset disease and in those with previous or current active vasculitis at univariate
analysis. Active small- or large- vessel vasculitis were the main independent variables
influencing PTX3 levels at multivariate analysis. High levels of PTX3 in the blood can
contribute to identify an increased risk of vascular involvement in patients with systemic
immune-mediated diseases.
Keywords: PTX3, autoimmunity, lupus, rheumatoid arthritis, Takayasu arteritis, giant cell arteritis, ANCA
associated small vessel vasculitis, intravascular immunity
INTRODUCTION
Vascular inflammation reflects the dynamic interaction of circulating cells, blood molecules and
vascular structures which plays a role in vascular homeostasis and in systemic or tissue/organ-
limited autoimmunity (1–5). The vasculature recruits cellular and immune effectors to facilitate
the intercellular signaling required to deploy an inflammatory and immune response (5, 6). Vessels
are frequently targeted in immune mediated-diseases, although in a subset of patients vascular
inflammation is prominent, resulting in overt vasculitis.
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Pentraxins are part of an ancestral humoral innate network,
evolutionarily rooted before the divergence of the immune and
the haemolymphatic system. Pentraxin-3 (PTX3), a member
of the long-pentraxin family, has changed little during the
evolution, likely due to its role in multiple biological events (7, 8).
In contrast to other pentraxins such as C-reactive protein (CRP),
PTX3 is mostly generated at sites of inflammation rather than
as a consequence of centralized hepatic synthesis. Neutrophils
massively release PTX3 upon activation, while endothelial
cells or macrophages synthetize the molecule, sustaining PTX3
production for longer times (9–11). In the extracellular space,
PTX3 opsonizes self and foreign antigens and contributes to
the structural and functional fitness of the extracellular matrix.
Evidence has been acquired for a potential pathogenic role of
PTX3 in a broad range of events from host defense to fertility,
cancer biology, autoimmunity, regulation of angiogenesis and
tissue repair (7, 12–19).
Enhanced expression of PTX3 has been reported in multiple
systemic autoimmune diseases (20–27). Given that most cellular
sources of PTX3 can be involved in vascular inflammation,
and that PTX3 has been shown to be specifically involved in
the regulation of the cross talk between the main players of
intravascular immunity, including neutrophils, apoptotic cells,
platelets, endothelial and antigen presenting cells (22, 28, 29), we
undertook an observational study assessing systemic expression
of PTX3 in healthy subjects and multiple inflammatory diseases
with variable vascular involvement.
PATIENTS AND METHODS
Upon written informed consent, 366 subjects followed up at
San Raffaele University Hospital, Milan, Italy were recruited
including: 96 patients with GCA, 42 with TA, 10 with
PMR, 38 with granulomatosis with polyangiitis (GPA), 15
with eosinophilic granulomatosis with polyangiitis (EGPA), 10
with microscopic polyangiitis (MPA), 55 with systemic lupus
erythematosus (SLE), and 21 with rheumatoid arthritis (RA).
Seventy-nine healthy volunteers served as controls. All patients
gave their written informed consent for participation in this
study (Autoimmuno-Mol protocol, approved by the Ethics
Committee of the San Raffaele Institute, Milan, Italy; reference
number 2/2013/INT). Patients were classified according to the
1990 American College of Rheumatology (ACR) classification
criteria for GCA and PMR (30), the 1996 Sharma’s diagnostic
criteria for TA (31), the European Medicine Agency algorithm
Abbreviations: AAV, ANCA-associated vasculitis; ACR, American College of
Rheumatology; ANCA, anti-neutrophil cytoplasmic antibodies; BILAG, British
Isles Lupus Assessment Group; BVAS, Birmingham Vasculitis Activity Score; CRP,
C-reactive protein; DAS-28, 28-joint disease activity score EGPA, eosinophilic
granulomatosis with polyangiitis; ESR, erythrocyte sedimentation rate; GPA,
granulomatosis with polyangiitis; HC, healthy controls; ITAS, Indian Takayasu
Activity Score; MPA, microscopic polyangiitis; PDN, prednisone; PGA, Physician’s
global assessment scale; PMR, polymyalgia rheumatica; PTX3, pentraxin-3; RA,
rheumatoid arthritis; SDI, SLICC/ACR damage index; SLE, systemic lupus
erythematosus; SLEDAI, SLE disease activity index; SLICC, SLE international
collaborating clinics; TA, Takayasu’s arteritis; TADS, TADamage Score; VAS, visual
analog scale; VDI, vasculitis damage index.
for classification of GPA, EGPA and MPA (32), the revised
1997 ACR or the 2012 SLE International Collaborating
Clinics (SLICC) classification criteria for SLE (33, 34) and
the 2010 ACR/European League Against Rheumatism(EULAR)
classification criteria for RA (35).
Basic demographics (including gender, age at sampling
and disease duration), disease activity and accrued irreversible
damage, dose of prednisone or equivalents, erythrocyte
sedimentation rate (ESR) and CRP values at time of sampling
were recorded. In patients with SLE, complement levels and
anti-DNA titres were collected. Disease activity for group
comparison was quantitated by employing a 28-joint disease
activity score (DAS-28) for RA, the SLE disease activity index
2000 version (SLEDAI-2K) for SLE (36), the Birmingham
Vasculitis Activity Score version 3 (BVAS v3) for anti-neutrophil
cytoplasm antibody (ANCA)-associated vasculitides (AAV)
(37) and the Indian Takayasu Activity Score for TA (ITAS2010)
(38). In patients with SLE, disease activity was also estimated by
employing the British Isles Lupus Assessment Group (BILAG)
2004 version index (39) and a 0.0-3.0 physician global assessment
scale (PGA). A 0-10 visual analog scale (VAS) also measured
SLE patients’ impression about their global health status. Organ
damage was determined by the SLICC/ACR Damage Index
(SDI) for SLE (40), the Vasculitis Damage Index (VDI) for AAV
and GCA (41) and the TA Damage Score (TADS) for TA (42).
Disease activity and damage scores were made homogeneous
by calculating Z-scores (i.e., x−mean
standard deviation
) for activity and
damage (Z-activity and Z-damage). In parallel to quantitative
assessment, a binary evaluation of disease activity and damage
was performed. The former was based on the Physician Global
Assessment of disease avidity (Inactive vs. Active/smoldering),
the latter by the presence vs. absence of items related to vasculitic
manifestations in the abovementioned scores. In patients
with SLE, lupus chilblains, skin/digital vasculitis/ischemia,
urticarial vasculitis, gastrointestinal vasculitis, choroidopathy or
retinal vasculitis, cerebral vasculitis and alveolar hemorrhage
were considered as relevant vasculitic manifestation, whereas
Raynaud’s phenomenon was not. In patients with AAV, “pure”
vasculitic manifestations included absence of ear-nose-throat
(ENT) or orbital involvement and presence of purpura, scleritis,
episcleritis, optic neuritis, renal involvement, peripheral
neuropathy, hemorrhagic alveolitis, or diagnosis of MPA.
PTX3 plasma levels were measured by a sandwich ELISA
based on original reagents developed in house. 96 well plates
(Nunc MaxiSorp cat. 446612) were coated with 100 µl anti-
hPTX3monoclonal antibody (MNB4 (43) 1µg/ml−100 ng/well)
in coating buffer (15mM carbonate buffer pH 9.6) and incubated
overnight at 4◦C. Plates were washed after each step with
300 µl/well of washing buffer (PBS 1X with Ca++ Mg++ +
0.05% Tween 20, pH 7.00). After coating, non-specific binding
to the plates was blocked with 5% dry milk in washing
buffer (2 h at room temperature), then 50 µl in duplicate
of recombinant human PTX3 standard (from 75 pg/ml to
2.4 ng/ml) and human plasma (diluted in PBS 1X w/o Ca++
Mg++ + 2% BSA, pH 7.00), were plated. 1 µl of 2.5%
Polybrene was added to 50 µl of plasma and incubated at
room temperature for 10min before dilution. After 2 h at
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TABLE 1 | General features of patients included in the study.
RA (n = 21) SLE (n = 55) PMR (n =
10)
AAV (n = 63) GCA (n = 96) TA (n = 42)
Age at diagnosis (year) ND 26.2
(18.6- 34.2)
72.0
(68.5- 73)
48.5
(36.5 - 61.5)
74.0
(67.0 - 77.0)
30.0
(24.0 - 40.5)
Age at sampling (years) 63.0
(43.0- 67.0)
38.2
(31.2- 48.9)
73.0
(69.3- 77)
59.5
(47.8 - 67.9)
75.2
(69.4 - 79.5)
46.0
(35 - 53)
ESR (mm/h) 16.5
(12.8 - 23.5)
20.0
(7.0 - 38.5)
30.0
(20.0 - 50.0)
13.0
(6.5- 31.5)
31.0
(18.0 - 57.8)
15
(7.8- 30.3)
CRP (mg/l) 3.5
(2 - 6.7)
2.1
(0.3 - 6.1)
10.4
(8.7 - 22.3)
0.8
(0.23 - 6.2)
11.0
(2.26 - 31.4)
2.25
(1.03 - 7.3)
PDN dose at sampling (mg/day) 5.0
(2.5 - 5)
3.8
(0.0 - 5.0)
1.9
(0.0 - 17.2)
5.0
(5.0 - 6.5)
5.0
(0.0 - 12.5)
5.0
(0.0 - 5.0)
Z-activity −0.42
(−0.47 - −0.28)
−0.33
(−0.56 - 0.35)
NA −0.4
(−0.4- −0.07)
−0.23
(−0.23 - −0.07)
−0.42
(−0.47 - −0.28)
Z-damage ND −0.2
(−0.2 - −0.07)
NA −0.06
(−0.06 - 0.01)
−0.14
(−0.14 - −0.06)
−0.12
(−0.57 - 0.19)
37◦C, plates were incubated with 100 µl /well of purified and
biotinylated rabbit IgG anti hPTX3 (5 ng/well) in washing
buffer (1 h at room temperature), followed by incubation with
100 µl/well-streptavidin conjugated to horseradish peroxidase
(cat. SB01-61, Biospa, Milan, Italy) diluted 1:2,000 in washing
buffer (1 h at room temperature). Finally, 100 µl of 1-StepTM
Ultra TMB-ELISA Substrate Solution (cat. 34029, Thermo
Scientific, Rockford, IL, USA) were added and the reaction was
blocked after 10min with 50 µl of 2M Sulphuric Acid (H2SO4)
before reading the plates at 450 nm in an automatic ELISA
reader. All the procedure was performed by personnel blind to
patients’ characteristics. For each biological sample, 2 dilutions
in duplicate wells were evaluated and mean PTX3 content was
calculated converting Abs450 values to protein concentration by
means of the standard curve with recombinant purified hPTX3.
Analysis was performed with SoftMax Pro software v5.3 (MDS
Analytical Technologies, USA) and linear regression was used
to interpolate unknown samples. Lower limit of detection of
the assay was 75 pg/ml, interassay variability was from 8 to
10%; no cross reaction was observed with short pentraxins CRP
and SAP.
PTX3 was measured in four different batches. Inter-batch
variability was corrected by normalization based on HC
samples. The relative frequencies of laboratory and clinical
categorical variables were compared by using chi-square test
with Fisher’s exact correction as appropriate. Quantitative
variables were compared by using Spearman’s correlation
tests. Differences in quantitative variables among groups were
assessed by employing Mann-Whitney U-test or Kruskal-
Wallis’ test for multiple comparisons. We also employed
generalized linear models with gamma distribution of the
dependent variables and log function as a link function to
assess the effect of each quantitative or qualitative variable on
PTX3 levels. Data were processed and analyzed by employing
Microsoft Excel R© 2013 and IBM SPSS R© version 15-23. Data
are expressed as median (interquartile range, IQR) unless
otherwise specified.
RESULTS
Expression of PTX3 in Systemic
Autoimmune Diseases
We enrolled 287 patients diagnosed with systemic autoimmune
diseases. Seventy-nine volunteers served as controls. Twenty-
one patients had RA, a systemic inflammatory disease targeting
the synovial membrane, 55 had SLE, the prototypic systemic
autoimmune disease, including 19 patients with vasculitic
features, ten had PMR, a fruste form of GCA with prominent
osteoarticular inflammation sparing the vasculature. Moreover,
we enrolled patients with primary systemic vasculitis of small
vessels (n= 63, including 38 with GPA, 15 with EGPA) and large
vessels (n= 138, including 96 with GCA and 42 with TA).Table 1
summarizes patients’ main characteristics.
PTX3 levels were significantly higher in patients with systemic
inflammatory immune-mediated and autoimmune diseases
(2.33 ng/ml, IQR: 1.26–4.89, n = 287) than in HCs (1.22 ng/ml,
IQR:0.80–1.98, n = 79; p < 0.001 ). However, despite often
comparable levels of systemic inflammation, PTX3 expression
was heterogeneous in patients with different diseases. RA and
PMR had plasma PTX3 levels comparable to those of HC. In
contrast, PTX3 plasma levels of patients with SLE, AAV, GCA,
and TA were significantly higher. Moreover, patients with SLE
had higher levels of PTX3 compared to patients with AAV, GCA
and TA (p<0.001 for AAV and TA, p= 0.001 for GCA; Figure 1).
PTX3 Correlates With Disease Activity but
Not With Accrued Damage
On univariate analysis in the general group of subjects who
had been studied, PTX3 levels were higher in females than in
males (Figure 2A) and did not correlate with disease duration
(Table 2). Patients with recent onset disease (i.e., up to 6 months)
had higher PTX3 levels compared to patients with longer disease
duration (Figure 2B). PTX3 levels positively correlated with Z-
activity (Rho= 0.181, p= 0.016, n= 176 Figure 3A), with acute
phase reactants (ESR and CRP, Rho = 0.229 and Rho = 0.128, p
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FIGURE 1 | PTX3 levels among different diseases. PTX3 plasma levels were
compared among patients with multiple distinct autoimmune diseases and HC.
Pairwise comparisons among groups are reported below. Patients with PMR
and RA did not differ from HC, whereas patients with other immune-mediated
diseases showed significantly higher levels of PTX3 compared to patients with
RA and HC. Patients with SLE had higher levels of PTX3 compared to patients
with large- (TA, GCA) and small-vessel vasculitides (AAV). AAV,
ANCA-associated vasculitides; GCA, giant cell arteritis; HC, healthy controls;
PMR, polymyalgia rheumatica; RA, rheumatoid arthritis; SLE, systemic lupus
erythematosus; TA, Takayasu’s arteritis; *p < 0.05; **p < 0.01; ***p < 0.001.
< 0.001 and p = 0.035, n = 261 and n = 269, respectively) and
with steroid dose (Rho = 0.198, p = 0.001, n = 259; Table 1 and
Figure 3B). On the contrary, PTX3 levels did not correlate with
Z-damage (Rho=−0.006, p= 0.930). PTX3 levels were higher in
patients with active disease as compared to those with quiescent
disease (3.28, IQR 1.27–7.21, n = 123 vs. 1.74, IQR: 1.07–3.16,
n = 222), while similar levels were observed in patients with
or without organ damage. Accordingly, PTX3 levels were higher
in patients with active disease and on corticosteroid treatment,
but did not differ between patients with or without chronic
damage (Figures 4A–C).
PTX3 Reflects Vascular Inflammation
Subjects with previous vasculitic manifestations had higher PTX3
levels than those without (2.3 ng/ml, IQR = 1.26–4.83, n =
220 vs. 1.43 ng/ml, IQR = 0.88–2.81, n = 146; p <0.001)
and patients with active vasculitis had higher levels of PTX3
compared to patients without evidence of vasculitis at time of
sampling (3.15 ng/ml, IQR = 1.31–7.75, n = 85 vs. 1.72 ng/ml,
IQR = 1.08–3.37, n = 278; p < 0.001 Figure 4D). PTX3 plasma
levels were higher either in patients with a history of small-
vessel inflammation (3.21 ng/ml, IQR = 1.57–6.58, n = 70)
or large vessel inflammation (2.27 ng/ml, IQR 1.12–4.29, n =
138) as compared to those without history of vasculitic features
(1.43 ng/ml, IQR = 0.88–2.81, n = 157; p < 0.001 and p
= 0.003, respectively, Figure 4E). Moreover, active small-vessel
inflammation (4.10 ng/ml, IQR = 2.16-8.09, n = 21) or active
large-vessel inflammation (2.49 ng/ml, IQR= 1.10–7.95, n= 64)
identified two subsets of patients with higher PTX3 plasma levels
than patients without active vascular inflammation (1.72 ng/ml,
IQR= 1.09–3.39, n= 281; p< 0.001 for both tests, Figure 4F).
PTX3 and Disease-Specific Clinical
Features
Both in SLE and AAV, pure vasculitic manifestations are not
detectable in all cases. Analysis of the patients with AAV revealed
a positive correlation of PTX3 and CRP levels (rho = 0.362; p
= 0.005, n = 58), ESR (rho = 0.272; p = 0.037, n = 59) and
ANCA titres at blood sampling (rho = 0.266; p = 0.049, n =
55). PTX3 also correlated with disease activity as measured by
BVAS in patients with GPA and MPA (rho = 0.362; p = 0.014,
n = 46). PTX3 levels were higher in patients with exclusive
vasculitic manifestations (3.51 ng/ml, IQR = 2.00–7.92, n = 16
vs. 1.83 ng/ml, IQR = 1.28–2.97 in patients with concomitant
granulomatous lesions, n = 47; p = 0.011) and lower in patients
with ear-nose-throat involvement (1.84 ng/ml, IQR = 1.32–2.97,
n= 43 vs. 3.37 ng/ml, IQR= 1.74–7.92, n= 20; p= 0.039).
PTX3 levels of patients with SLE correlated with disease
activity as assessed by SLEDAI-2K in the whole group of patients
(rho = 0.361; p = 0.007, n = 55) and in those who were off
corticosteroids (p < 0.001, n = 19; Table 3), but not in patients
receiving prednisone. In the latter patients, a positive correlation
was observed between PTX3 levels and prednisone dose (rho =
0.198; p= 0.001, n= 36). Patients with >1 moderately-to-highly
active (A, B) BILAG domain had significantly higher PTX3 levels
than those with more limited disease activity extent (7.23 ng/ml,
IQR = 5.51–9.58, n = 9 vs. 4.29 ng/ml. IQR = 3.09–6.34, n =
46; p = 0.041). PTX3 also directly correlated with PGA (rho =
0.383; p = 0.004, n = 55) and inversely with patient-reported
VAS (rho = −0.331; p = 0.013, n = 55) and C4 levels (rho =
−0.458; p = 0.001, n = 51). There was no significant correlation
with age, disease duration or with CRP concentration or anti-
DNA antibodies titres (Table 3). CRP was higher in patients with
>1 A/B BILAG domain (p= 0.004), but its concentration did not
correlate with SLEDAI-2K or prednisone dose. SLE patients with
active disease tended to have higher levels of PTX3 compared
to patients with inactive disease. This trend was more evident in
patients with past or current evidence of vascular inflammation
(Supplementary Figure 1).
PTX3 Levels Reflect Small- and
Large-Vessel Inflammation at
Multivariate Analysis
We performed two multivariate linear regressions of PTX3
plasma levels with a stepwise backward approach. The first
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FIGURE 2 | PTX3 levels and demographics. These panels show the existing differences in systemic expression of PTX3 by selected demographics. PTX3 levels were
higher in females (A) and in patients with early-onset disease (B). *p < 0.05.
TABLE 2 | Correlations among PTX3 plasma levels and clinical features at
univariate analysis.
Variable Spearman’s Rho p
Age (years) NS NS
Age at disease onset (years) NS NS
Z-score (activity) 0.181 0.016
Z-score (damage) NS NS
ESR (mm/h) 0.229 0.0002
CRP (mg/l) 0.128 0.035
Prednisone dose (mg) 0.198 0.001
regression included sex, diagnosis, disease activity, history and
activity of small-vessel inflammation, history, and activity of
large-vessel inflammation, and steroid therapy. The stepwise
algorithm resulted in a model including disease activity (B =
3.162, Std.Err = 0.738, p<0.001) and activity of small vessel
inflammation (B= 4.200, Std.Err= 1.579, p= 0.008). In a second
iteration, disease activity was excluded due to high colinearity
with the other variables. The final regression model (Table 4)
included activity of small vessel inflammation (B= 6.706, Std.Err
= 1.473, p < 0.001), activity of large vessel inflammation (B =
4.269, Std.Err = 0.844, p = 0.008), and diagnosis (B = 0.243,
Std.Err= 0.121, p= 0.046).
DISCUSSION
In this brief report, we present a multi-disease comparison
of PTX3 plasma profile in patients with various systemic
autoimmune and inflammatory conditions. In line with previous
evidence from other groups and us (20, 21, 23, 24, 26, 44–
46), we observed that PTX3 levels rise in acutely inflamed
patients. Accordingly, PTX3 levels are higher in patients with
recent onset disease [see also (23, 47)] and correlated with
disease activity and with conventional inflammatory markers
such as ESR and CRP. However, PTX3 blood levels do not
merely reflect systemic inflammation, and indeed they failed to
increase in conditions such as RA and PMR. The relative lack
of PTX3 increase well-agrees with the role of PTX3 as a tissue-
generated signal: the inflamed synoviae possibly represent the
preferential site of PTX3 generation and it has been reported
that PTX3 assessment in the synovial fluid might indeed be more
informative (27, 48).
Clinically overt vascular inflammation involving small or large
vessels was associated with elevated PTX3 levels. Identification
of reliable biomarkers for vascular inflammation assessment
constitutes a significant unmet need in current Rheumatology
practice (49–55). The present study supports the contention
that vascular inflammation is a major driver of PTX3 elevation
(20, 23, 56).
Patients with SLE had the highest PTX3 levels. PTX3
correlated with active SLE as estimated by the number of high-
score BILAG domains. Aberrant presentation of autoantigens
due to non-physiological release of PTX3 (13, 28, 57) could
be involved, as indicated by the protective role of anti-PTX3
antibodies in SLE (58, 59). Corticosteroids are major inducers
of PTX3 at a systemic level (60) and can constitute an
additional modulatory variable in this setting. In particular,
systemic administration of corticosteroid drugs or exposure to
higher endogenous glucocorticoid levels cause an overall rise in
blood PTX3 levels. Nonetheless, glucocorticoids have divergent
effects on different cell types as they dampen PTX3 expression
in monocyte-derived dendritic cells, but significantly induce
PTX3 in endothelial cells and fibroblasts (60). Consistently,
corticosteroids also exert distinct biological effects over different
pathogenic backgrounds (61). Alternatively, smoldering vascular
inflammation might be advocated as a potential explanation for
plasma PTX3 elevation in patients with SLE and for conflicting
results in the literature regarding associations with clinically
overt vasculitis (26, 62–65).
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FIGURE 3 | Correlations with PTX3 levels. PTX3 correlated with multiple disease and treatment-related variables at univariate analysis. (A) Depicts the linkage between
increasing normalized activity score (Z-activity) and PTX3 plasma levels. (B) Shows the potential influence of corticosteroid treatment on PTX3 circulating levels.
FIGURE 4 | PTX3 levels and disease phenotypes. In this multi-panel graph, differences in PTX3 plasma levels among phenotype groups are highlighted. PTX3 levels
were higher in patients with active disease (A), but not with accrued irreversible damage (B). PTX3 was also higher in patients on corticosteroids (C). (D) Depicts the
existing differences between patients with vs. without a history of vasculitis and between active or quiescent vasculitis at time of sampling. In (E,F) patients are
stratified according to a history (E) or ongoing activity (F) of small- or large-vessel vasculitis associated with higher levels of PTX3 when compared to no vasculitis.
*p < 0.05; **p < 0.01; ***p < 0.001.
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TABLE 3 | Correlations among PTX3 levels and clinical variables in patients
with SLE.
Correlation with PTX3
All patients Patients on PDN
Age No No
Disease duration No No
SLEDAI-2K Yes No
PGA Yes No
Patient’s VAS Yes (inverse) No
Erythrocyte sedimentation rate No No
CRP levels No No
C3 levels No No
C4 levels Yes (inverse) No
Anti-DNA titres No No
PDN dose No Yes
TABLE 4 | Multivariate linear model of PTX3 levels.
B Std. error p-value
Active small-vessel inflammation 6.706 1.473 <0.001
Active large-vessel inflammation 4.269 0.844 0.008
Diagnosis 0.243 0.121 0.046
History of small-vessel inflammation 1.148 1.122 0.307
History of large-vessel inflammation 0.607 0.862 0.482
Sex −0.354 0.750 0.637
Steroid therapy −0.260 0.828 0.754
R2 of the model including the significant variables: 0.122.
Single tissue/organ-limited inflammatory events not involving
the vascular bed might not represent effective stimuli for PTX3
elevation in the circulating blood. In line with this view,
relatively low PTX3 concentrations were found in plasma from
patients with RA, PMR and AAV without vasculitic features
in this and other studies (20, 44). Neutrophil, endothelial
cells and vessel-residing mononuclear cells can all concur
to PTX3 release in the circulating blood during acute and
chronic vascular injury (8, 11). PTX3 might be part of a
protective response to the extension and exacerbation of organ
damage due to post-ischemic inflammation (21, 29). However,
PTX3 can also promote vascular injury under septic conditions
(66). Furthermore, as a constituent of the antimicrobial array
embedded in neutrophil extracellular traps (NETs) (10), PTX3
can concur to NETs-related immunothrombosis (58, 67) and
similarly to neutrophil myeloperoxidase and proteinase-3 (which
are also enclosed in NETs), promote the generation of pathogenic
antibodies (68). Anti-PTX3 antibodies have been proposed
represent atypical ANCA and, in contrast to SLE, might correlate
with disease activity in patients with AAV (69).
This study has limitations. Systemic diseases without primary
vessel inflammation are relatively underrepresented, which
warrants caution in the interpretation of PTX3 dynamics in
these settings. In addition, this study only explored the clinical
relevance of PTX3 as a biomarker of vascular inflammation,
without any deeper insight into the pathogenic drivers of
this phenotype. Further mechanistic studies are thus needed
to address this issue and possibly refine our knowledge on
potential applications of PTX3 in diagnostics and therapy. To this
purpose, dissecting the role of glucocorticoids as confounding
factors for PTX3 expression would be of particular relevance,
due to the widespread use of corticosteroid drugs in immune-
mediated diseases.
Taken together, these data suggest that PTX3 could be
implicated in multiple distinct pathophysiological events causing
and maintaining inflammation in immune-mediated diseases.
From a diagnostic point of view, PTX3 elevation in the circulating
blood marks the occurrence of inflammatory events in blood
vessels and might find a specific niche in clinical practice
as a tool to identify vasculitic subsets among patients with
autoimmune diseases.
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activity, history of vascular inflammation and vasculitic activity. Patients with active
disease not comprising any vascular involvement (V.I.) and patients with active
vascular involvement in SLE showed a trend toward higher PTX3 levels compared
to patients with clinically quiescent disease.
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